MX2009005205A - Conjugado de polietilenglicol-g-csf. - Google Patents

Conjugado de polietilenglicol-g-csf.

Info

Publication number
MX2009005205A
MX2009005205A MX2009005205A MX2009005205A MX2009005205A MX 2009005205 A MX2009005205 A MX 2009005205A MX 2009005205 A MX2009005205 A MX 2009005205A MX 2009005205 A MX2009005205 A MX 2009005205A MX 2009005205 A MX2009005205 A MX 2009005205A
Authority
MX
Mexico
Prior art keywords
polyethylene glycol
peg
csf conjugate
csf
mol
Prior art date
Application number
MX2009005205A
Other languages
English (en)
Inventor
Yeong-Woo Jo
Won-Young Yoo
Hyun-Kyu Jeon
Yun-Kyu Choi
Hye-In Jang
Byong-Moon Kim
Sung-Hee Lee
Soo-Hyung Kang
Moo-Hi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of MX2009005205A publication Critical patent/MX2009005205A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se reviere al conjugado de PEG de tres ramificaciones-G-PEG de la fórmula general (I) en la cual la relación de unión del polietileno glicol de tres ramificaciones (PEG) y G-CSF es 1:1 (mol/mol), en donde PEG tiene un peso molecular promedio de 200 a 45,000 daltons; una composición farmacéutica que comprende los mismos y un método de preparación de la misma.
MX2009005205A 2006-11-17 2006-11-22 Conjugado de polietilenglicol-g-csf. MX2009005205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060113721A KR101079993B1 (ko) 2006-11-17 2006-11-17 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
PCT/KR2006/004908 WO2008060002A1 (en) 2006-11-17 2006-11-22 Polyethylene glycol-g-csf conjugate

Publications (1)

Publication Number Publication Date
MX2009005205A true MX2009005205A (es) 2009-05-28

Family

ID=39401799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005205A MX2009005205A (es) 2006-11-17 2006-11-22 Conjugado de polietilenglicol-g-csf.

Country Status (13)

Country Link
US (1) US8329191B2 (es)
EP (1) EP2081580B1 (es)
JP (1) JP5363987B2 (es)
KR (1) KR101079993B1 (es)
CN (1) CN101616678B (es)
AU (1) AU2006350790B2 (es)
BR (1) BRPI0622128A2 (es)
ES (1) ES2433253T3 (es)
MX (1) MX2009005205A (es)
PL (1) PL2081580T3 (es)
RU (1) RU2423133C2 (es)
UA (1) UA93284C2 (es)
WO (1) WO2008060002A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2415800T3 (da) * 2009-03-31 2013-12-02 Nof Corp Hyperforgrenet polyoxyalkylenforbindelse og fremgangsmåde til deres fremstilling
DK2947111T3 (en) * 2013-01-17 2018-05-07 Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
US9319147B2 (en) 2014-06-30 2016-04-19 Alcatel Lucent Optical receiver for quadrature-phase-shift-keying and quadrature-duobinary signals
TWI758285B (zh) * 2016-04-15 2022-03-21 大陸商江蘇恆瑞醫藥股份有限公司 一種重組人粒細胞刺激因子的復性及純化方法
US11267859B2 (en) * 2017-06-09 2022-03-08 The Regents Of The University Of Colorado, A Body Corporate GM-CSF mimetics and methods of making and using same
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
WO2023055081A1 (ko) * 2021-09-28 2023-04-06 한양대학교 산학협력단 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2002540065A (ja) 1999-01-29 2002-11-26 アムジェン インコーポレーテッド Ｇｃｓｆコンジュゲート
CN1321134C (zh) * 2000-11-23 2007-06-13 赵剑 一种生物活性蛋白质的非均一制品及其制备方法
CN1176137C (zh) 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
US7557195B2 (en) 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
KR101237884B1 (ko) * 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
JP2008511610A (ja) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法

Also Published As

Publication number Publication date
ES2433253T3 (es) 2013-12-10
JP2010510204A (ja) 2010-04-02
JP5363987B2 (ja) 2013-12-11
EP2081580A1 (en) 2009-07-29
AU2006350790B2 (en) 2010-04-29
UA93284C2 (uk) 2011-01-25
EP2081580A4 (en) 2011-08-10
HK1138799A1 (en) 2010-09-03
PL2081580T3 (pl) 2014-01-31
RU2423133C2 (ru) 2011-07-10
EP2081580B1 (en) 2013-08-14
RU2009122976A (ru) 2010-12-27
KR20080044639A (ko) 2008-05-21
AU2006350790A1 (en) 2008-05-22
WO2008060002A1 (en) 2008-05-22
US8329191B2 (en) 2012-12-11
CN101616678A (zh) 2009-12-30
BRPI0622128A2 (pt) 2011-12-27
KR101079993B1 (ko) 2011-11-04
CN101616678B (zh) 2012-10-03
US20100105616A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
EP1604989A8 (en) DPP-IV inhibitors
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
MXPA05003394A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos.
WO2007019331A3 (en) Conjugates of a g-csf moiety and a polymer
MX2012000644A (es) Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion.
PL1758553T3 (pl) Kompozycje farmaceutyczne zawierające glikol polietylenowy o masie cząsteczkowej niższej niż 600 Daltonów
WO2008024435A3 (en) Dendritic molecular intracellular transporters and methods of making and using same
WO2004050058A3 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
IL229304A (en) Compounds 1 ', 3' - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1'h, [1, 4 '] Bipyridinyl - 2' - lozenges, pharmaceutical preparations containing them and their use
MXPA03008886A (es) Composiciones de baja respuesta glicemica.
MX347056B (es) Composiciones farmaceuticas.
IL210452A (en) Annotations of dimethyl-oxo-dihydro- (pyridine-3-or-4-ram) -phenyl-6-methyl-6-phenyl- [1,3] -oxiazine-2-one
WO2011062965A8 (en) Targeting monomers and polymers having targeting blocks
MA34832B1 (fr) Compositions biodegradables d'administration de medicaments
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
IL178722A0 (en) Compressed pharmaceutical compositions comprising peg and electrolytes
WO2008017381A8 (de) Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
JP2014501765A5 (es)
EP2199338A3 (en) Polyetheralkanolamine dispersants
WO2010038091A3 (en) Compositions comrrising amlodipine and bisoprolol
EP1604980A8 (en) DPP-IV inhibitors
JP2014503548A5 (es)
MX2009005205A (es) Conjugado de polietilenglicol-g-csf.
ZA200707973B (en) Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids

Legal Events

Date Code Title Description
FG Grant or registration